NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc ("ADMA Biologics" or "the Company") (NASDAQ:ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc ("ADMA Biologics" or "the Company") (NASDAQ:ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
Adma Biologics (ADMA) closed the most recent trading day at $15.62, moving -1.01% from the previous trading session.
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.